Neurology
Alzheimer’s Treatment Moves Home. Risk Does Not.
FDA approval of Leqembi Iqlik as a subcutaneous initiation dose could reduce infusion burden in early Alzheimer’s disease. But moving treatment closer to home does not make anti-amyloid care simple.
Europe Opens the SMA Gene-Therapy Door Wider
ALS Needs Proof, Not Just Another Biomarker
For Pompe Infants, Time Is the Comparator
Alzheimer’s Trials Still Measure Too Little, Too Late
Eight Patients Cannot Solve Alzheimer’s. They Can Tell Us What the Next Trial Must Prove.
The ICU Has a New Signal. It Is Not a Verdict.
The Trial Has Started. Now the System Has to Find the Children.
Sleep is now cardiovascular prevention. Health systems still treat it like lifestyle advice
ADHD Does Not Stop Being ADHD When Anxiety Walks Into the Room
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.